Asthma MedDRA version: 12.0 Level: LLT Classification code 10003553 Term: Asthma
Conditions
Interventions
Product Name: Fluticasone furoate/GW642444 Inhalation Powder
Product Code: Fluticasone furoate (GW685698)/GW642444
Pharmaceutical Form: Inhalation powder, pre-dispensed
INN or Proposed INN: Fluticason
Sponsors
GlaxoSmithKline Research & Development Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type of Subject: Outpatient 2. Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regulations or the regulatory status of study medication permit enrolment of adults only; in Germany: 18 years of age or older). 3. Gender: Male or eligible female To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: • Male partner who is sterile prior to the female subject’s entry into the study and is the sole sexual partner for that female subject • Implants of levonorgestrel or etonogestrel • Injectable progestogen • Oral contraceptive (either combined estrogen/progestin or progestin only) • Any intrauterine device (IUD) with a documented failure rate of less than 1% per year • Estrogenic vaginal ring • Double barrier method – spermacide plus a mechanical barrier (e.g., spermacide plus a male condom or spermacide and female diaphragm) • Percutaneous contraceptive patches • Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial and for a period after the trial to account for elimination of the drug (minimum of six days) • Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation. A serum pregnancy test is required for females of childbearing potential at the initial screening visit (Visit 1), Visit 5, Visit 7, Visit 10 and Visit 13/Early Withdrawal. A urine pregnancy test will be performed at Visits 2 through 4, Visits 8 through 9, Visits 11 through 12 and the follow-up contact. 4. Asthma Diagnosis: A diagnosis of asthma as defined by the National Institutes of Health at least 1 year prior to Visit 1. 5. Severity of Disease: A best FEV1 of 50% to 90% of the predicted normal value at Visit 1. NHANES III predicted values will be used for subjects =12 years of age. If a subject is recorded as having Hispanic or Latino ethnicity, then the Mexican-American equations will be used (irrespective of race). If a subject is recorded as being of African American/African Heritage race, then the African American equations will be used. If a subject is recorded as being of Asian race, then the Asian equations will be used. Otherwise, the Caucasian equations will be used. 6. Reversibility of Disease: Demonstrated a =12% and =200mL reversibility of FEV1 within 10 to 40 minutes following 2 to 4 inhalations of albuterol/salbutamol inhalation aerosol (if required, spacers are permitted for reversibility testing only) or equivalent nebulized treatment with albuterol/salbutamol solution at screening. 7. Current Anti-Asthma Therapy: Subjects must be using an approved dose of an ICS (as per specific prescribing information) for at least 12 weeks preceding Visit 1 and at a stable dose for at least 4 weeks preceding Visit 1 for further information See protocol page 19. 8. Asthma Exacerbation History: All subjects must have a history of one or more asthma exacerbations requiring treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization for the treatment of asthma within the previous 12 months. Note: Subjects who have experienced an asthma exacerbation requiring oral/systemic oral corticosteroids in the 4 weeks prior to Visit 1 can not be enrolled in the study due to the 4 week washout of the oral/systemic
Exclusion criteria
Exclusion criteria: 1. History of Life-Threatening Asthma: Defined for this protocol as an asthma episode that required intubation and/or associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 5 years. 2. Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or respiratory abnormalities other than asthma. 3. Other Concurrent Diseases/Abnormalities: A subject must not have any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study. 4. Oral Candidiasis: A subject will not be eligible for the run-in if he/she has clinical visual evidence of oral candidiasis at Visit 1. 5. Investigational Medications: A subject must not have participated in a study (including a non-interventional study) or used any investigational drug (including devices) within 30 days prior to Visit 1 or within ten half-lives (t1/2) of the prior investigational study (whichever is longer of the two). 6. Previous Participation: A subject may not have previously been randomized to treatment in a Phase III Fluticasone Furoate/GW642444 Inhalation Powder study (i.e., HZA106825, HZA106827, HZA106829, HZA106839, HZA106851). 7. Drug Allergy: Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the Novel Dry Powder Inhaler (i.e., lactose or magnesium stearate). 8. Milk Protein Allergy: History of severe milk protein allergy. 9. Immunospressive medications: A subject must not be using or require use of immunosuppressive medications during the study. Note: Immunotherapy for the treatment of allergies is allowed during the study provided it was initiated 4 weeks prior to Visit 1 and subjects remain in the maintenance phase for the duration of the study. 10. Attendance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability or geographical location which seems likely (in the opinion of the investigator) to impair compliance with any aspect of this study protocol or scheduled visits to the study center and non-compliance with study medication or procedures (i.e., completion of diary card). 11. Neurological or psychiatric disease or history of drug or alcohol use which would interfere with the subjects’ proper completion of the protocol requirements. 12. Concomitant Medications: Administration of any other prescription or over the counter medication which would significantly affect the course of asthma, or interact with sympathomimetic amines, such as: anticonvulsants (barbiturates, hydantoins, carbamazepine), polycyclic antidepressants, beta-adrenergic blocking agents (both cardio-selective and non-selective), phenothiazines, monoamine oxidase (MOA) inhibitors. Please refer to the SPM for further details. 13. Tobacco Use: A subject may not have used inhaled tobacco products within the past three months (i.e., cigarettes, cigars or pipe tobacco) or have historical use of 10 pack years or more (e.g., 20 cigarettes/day for 10 years). 14. Affiliati
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to demonstrate that treatment with Fluticasone Furoate/GW642444 Inhalation Powder once-daily administered in the evening significantly decreased the risk of severe asthma exacerbations as measured by time to first severe asthma exacerbation when compared with the same dose of Fluticasone Furoate Inhalation Powder alone administered once-daily in the evening in subjects 12 years of age and older with asthma. This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.;Secondary Objective: None;Primary end point(s): The primary efficacy endpoint of this study is the time to first severe asthma exacerbation. | — |
Countries
Germany
Outcome results
None listed